Terms: = Lung cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
131 results:
1. [Correlation between prognostic nutritional index and pleural thickness with survival time of epithelial malignant pleural mesothelioma patients].
Zhou JH; Zhang YL; Li LF; Lu PL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Feb; 42(2):118-123. PubMed ID: 38403420
[No Abstract] [Full Text] [Related]
2. Prediction of Microwave Ablation Recurrence in Pulmonary Malignancies Using Preoperative Computed Tomography Radiomics Models.
Zhu F; Yang C; Yang J; Mao H; Huang Y; Liu H; Zhao Z
Curr Med Imaging; 2024; 20():1-26. PubMed ID: 38389378
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of a clinic-radiological model to predict tumor spread through air spaces in stage I lung adenocarcinoma.
Gao Z; An P; Li R; Wu F; Sun Y; Wu J; Yang G; Wang Z
Cancer Imaging; 2024 Feb; 24(1):25. PubMed ID: 38336821
[TBL] [Abstract] [Full Text] [Related]
4. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
Yang Y; Wang J; Wang J; Zhao X; Zhang T; Yang Y; Pang J; Ou Q; Wu L; Xu X; Xu K; Zhao J; Bai N; Yang P; Wang S; Wang L; Bi N
Cancer Lett; 2024 Feb; 582():216569. PubMed ID: 38101608
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic Impact of cancer Inflammation Prognostic Index for Non-small Cell lung cancer.
Motono N; Mizoguchi T; Ishikawa M; Iwai S; Iijima Y; Uramoto H
Lung; 2023 Dec; 201(6):603-610. PubMed ID: 37906295
[TBL] [Abstract] [Full Text] [Related]
6. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC.
Deininger K; Raacke JN; Yousefzadeh-Nowshahr E; Kropf-Sanchen C; Muehling B; Beer M; Glatting G; Beer AJ; Thaiss W
Nuklearmedizin; 2023 Oct; 62(5):284-292. PubMed ID: 37696296
[TBL] [Abstract] [Full Text] [Related]
7. PET-CT SUV
Faria N; Lacerda C; Lopes J; Viana C; Sucena M
Clin Lung Cancer; 2023 Dec; 24(8):753-760. PubMed ID: 37599163
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
Cheng Y; Chen ZY; Huang JJ; Shao D
Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
[TBL] [Abstract] [Full Text] [Related]
9. FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell lung cancer.
Tan W; Zhang Y; Wang J; Zheng Z; Xing L; Sun X
Acad Radiol; 2023 Dec; 30(12):2904-2912. PubMed ID: 37202226
[TBL] [Abstract] [Full Text] [Related]
10. Primary tumor SUV
Tas F; Ozturk A; Erturk K
Wien Klin Wochenschr; 2023 Sep; 135(17-18):478-487. PubMed ID: 36882606
[TBL] [Abstract] [Full Text] [Related]
11. Respiratory muscle metabolic activity on PET/CT correlates with obstructive ventilatory defect severity and prognosis in patients undergoing lung cancer surgery.
El Husseini K; Baste JM; Bouyeure-Petit AC; Lhuillier E; Cuvelier A; Decazes P; Vera P; Similowski T; Patout M
Respirology; 2023 Jun; 28(6):551-560. PubMed ID: 36855939
[TBL] [Abstract] [Full Text] [Related]
12. Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.
Ekman S; Cselényi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnström P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
Clin Transl Sci; 2023 Jun; 16(6):955-965. PubMed ID: 36808835
[TBL] [Abstract] [Full Text] [Related]
13. Construction and Preclinical Evaluation of a
Yao Y; Hou X; Liu S; Liu T; Ren Y; Ma X; Zhang Q; Wang P; Guo Q; Ma X; Yang Z; Zhu H; Li N
Mol Pharm; 2023 Feb; 20(2):1365-1374. PubMed ID: 36579764
[TBL] [Abstract] [Full Text] [Related]
14. Distinct Prognostic Impact of PET Findings Based on Radiological Appearance in Clinical Stage IA lung Adenocarcinoma.
Nakao M; Terauchi T; Oikado K; Sato Y; Hashimoto K; Ichinose J; Matsuura Y; Okumura S; Ninomiya H; Mun M
Clin Lung Cancer; 2023 Mar; 24(2):107-113. PubMed ID: 36496335
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract] [Full Text] [Related]
16. Deep multiple instance learning for predicting chemotherapy response in non-small cell lung cancer using pretreatment CT images.
Chang R; Qi S; Wu Y; Song Q; Yue Y; Zhang X; Guan Y; Qian W
Sci Rep; 2022 Nov; 12(1):19829. PubMed ID: 36400881
[TBL] [Abstract] [Full Text] [Related]
17. Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience.
Cimen F; Agackiran Y; Düzgün S; Aloglu M; Senturk A; Atikcan S
Medicine (Baltimore); 2022 Sep; 101(39):e30711. PubMed ID: 36181042
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic Potential of Metabolic Activity on 18 F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade.
Hashimoto K; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Yamaguchi O; Kobayashi K; Kagamu H; Kuji I
J Immunother; 2022 Oct; 45(8):349-357. PubMed ID: 35980360
[TBL] [Abstract] [Full Text] [Related]
19. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
Flörsch B; Taugner J; Käsmann L; Kenndoff S; Guggenberger J; Tufman A; Reinmuth N; Duell T; Belka C; Eze C; Manapov F
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3267-3276. PubMed ID: 35915184
[TBL] [Abstract] [Full Text] [Related]
20. The correlation between PD-L1 expression and metabolic parameters of
Xu X; Li J; Yang Y; Sang S; Deng S
Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
[TBL] [Abstract] [Full Text] [Related]
[Next]
